Cerdelga (Eliglustat)

Cerdelga (eliglustat) is a glucosylceramide synthase inhibitor used for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs).

Limitations of Use:
CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of Eliglustat to achieve a therapeutic effect.
A specific dosage cannot be recommended for CYP2D6 indeterminate metabolizers.

Recommended Dosage:
The recommended dosage of Eliglustat in adult patients is based on the patient’s CYP2D6 metabolizer status. The right dose depends on how your body processes the medicine. This is simply determined by a test known as CYP2D6 testing, which your clinician will do before beginning treatment.

• If your body breaks down the medicine normally (called EM or IM): You’ll take CERDELGA 84 mg two times daily – once in the morning and once at night.
• If your body breaks down the medicine slowly (called PM): You’ll take CERDELGA 84 mg once a day, usually recommended at the same time every day.

Note: CYP2D6 testing is important to ensure the dose is safe and effective for you. Always follow your doctor’s advice before starting or adjusting your dose.

• Treatment with Eliglustat may be responsible for affecting heart rhythm and causing QT interval changes. This therapeutic drug should not be used in those with certain heart complications. ECG monitoring is required before initiating treatment, particularly for those on other medicines that affect the heart's electrical activity.
• Pregnant women have not been studied under well-controlled circumstances with Eliglustat. Studies on animals show risks. It should only be prescribed during pregnancy if the potential benefits justify the risks, which in this case would be the unborn baby’s risk. Consultations with a clinician are always a necessity before use.
• It is not specified whether this medicine passes into human breast milk. Because many medicines can be passed to infants through breast milk, it's best to avoid using this medicine while breastfeeding, unless your healthcare provider (HCP) believes the benefits outweigh the possible risks to the baby.
• Eliglustat 84 mg has not been studied in children or adolescents under 18 years. Therefore, its safety and effectiveness in this age population are not known. It is not recommended for use in pediatric patients until more data becomes available through clinical research.
• Limited studies exist in patients aged 65 and older. While no overall differences were noticed, older adults may have other health complications or use additional medicines, which can affect how this medicine works. Caution is required, and close monitoring must be done.
• Treatment with this medicine has not been adequately studied in those with kidney disease. Its use in those with moderate to severe renal impairment is not required because of a lack of safety data. Patients with kidney complications must discuss risks and options with their clinician.
• Patients who have mild to moderate liver impairment are at risk for having altered drug metabolism of Eliglustat because the drug is metabolized in the liver; therefore, its use is not recommended in these patients. Liver disease of moderate to severe grades poses a risk for worsening drug metabolism; thus, these patients should not be prescribed such medications.

What documents are required to import CERDELGA to India?

CERDELGA (eliglustat) capsules can be imported by patients or government hospitals in the name of the patients only.

• The following documentation is required to import the product:
• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is CERDELGA available in India?

CERDELGA (eliglustat capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Cerdelga in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

CERDELGA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of CERDELGA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Cerdelga 84 mg Capsule price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source CERDELGA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Cerdelga®?

Eliglustat is the Generic Name for the trade name drug Cerdelga®.

What is the Manufacturer's Name of Cerdelga®?

Cerdelga® is manufactured by Genzyme Corporation.

Is Cerdelga® approved by the FDA?

Yes. Cerdelga® approved by the FDA. Date of initial approval: August 19, 2014.

What is the dosage and form of Cerdelga® supplied?

Cerdelga is supplied in Capsules: 84 mg of eliglustat for oral administration.

What are the most common side effects of Cerdelga® 84 mg Capsule?

The most common side effects of Cerdelga® are fatigue, diarrhea, headache, nausea, pain in the extremities, back pain, and upper abdominal pain.

How much does Cerdelga® 84 mg Capsule cost in India?

Cerdelga® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Prices of Cerdelga Capsules may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Cerdelga 84 mg cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Cerdelga® 84 mg Capsules be available in SAARC countries?

Apart from Gulf countries, Cerdelga® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Cerdelga® capsules in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Cerdelga® 84 mg Capsules online in India?

Yes, one can buy Cerdelga 84 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Cerdelga® Capsule through legal channels.

What are the storage conditions of Cerdelga® 84 mg Capsules?

Store the capsules at room temperature between 68°F and 77°F (20°C to 25 °C). Keep it and all other medicines out of reach of children.